+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Respiratory Disease Vaccine Market Research Report by Infection (Influenza Virus, Pertussis, and Streptococcus Pneumoniae), Type, Age Group, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 249 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 5012997
UP TO OFF until Dec 31st 2022
The Global Respiratory Disease Vaccine Market size was estimated at USD 20.98 billion in 2021, USD 22.16 billion in 2022, and is projected to grow at a CAGR 5.76% to reach USD 29.38 billion by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Respiratory Disease Vaccine to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Infection, the market was studied across Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis.
  • Based on Type, the market was studied across Bacterial Vaccine, Combination Vaccine, and Viral Vaccine.
  • Based on Age Group, the market was studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Respiratory Disease Vaccine market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Respiratory Disease Vaccine Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Respiratory Disease Vaccine Market, including AstraZeneca, Bavarian Nordic, Bayer AG, Bio Farma, Dynavax Technologies Corporation, Emergent BioSolutions, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Seqirus USA Inc., and Serum institute of India Private Limited.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Respiratory Disease Vaccine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Respiratory Disease Vaccine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Respiratory Disease Vaccine Market?
4. What is the competitive strategic window for opportunities in the Global Respiratory Disease Vaccine Market?
5. What are the technology trends and regulatory frameworks in the Global Respiratory Disease Vaccine Market?
6. What is the market share of the leading vendors in the Global Respiratory Disease Vaccine Market?
7. What modes and strategic moves are considered suitable for entering the Global Respiratory Disease Vaccine Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of respiratory disorders
5.1.1.2. Clinical trials and vaccines developments in pipeline
5.1.1.3. Government initiatives supporting respiratory health
5.1.2. Restraints
5.1.2.1. Lack of inadequate delivery infrastructure & limited awareness
5.1.3. Opportunities
5.1.3.1. Increasing R&D expenditure by leading companies
5.1.3.2. Increase vaccine availability through reselling collaborations
5.1.4. Challenges
5.1.4.1. Consumer trust & confidence in respiratory disease vaccination
5.2. Cumulative Impact of COVID-19
6. Respiratory Disease Vaccine Market, by Infection
6.1. Introduction
6.2. Influenza Virus
6.3. Pertussis
6.4. Streptococcus Pneumoniae
6.5. Tuberculosis
7. Respiratory Disease Vaccine Market, by Type
7.1. Introduction
7.2. Bacterial Vaccine
7.3. Combination Vaccine
7.4. Viral Vaccine
8. Respiratory Disease Vaccine Market, by Age Group
8.1. Introduction
8.2. Adolescent Vaccination
8.3. Adult Vaccination
8.4. Infant Vaccination
9. Americas Respiratory Disease Vaccine Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Respiratory Disease Vaccine Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Respiratory Disease Vaccine Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AstraZeneca
13.2. Bavarian Nordic
13.3. Bayer AG
13.4. Bio Farma
13.5. Dynavax Technologies Corporation
13.6. Emergent BioSolutions, Inc.
13.7. GlaxoSmithKline plc
13.8. Merck & Co., Inc.
13.9. Pfizer Inc.
13.10. Sanofi S.A.
13.11. Seqirus USA Inc.
13.12. Serum institute of India Private Limited
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2021 VS 2027 (USD BILLION)
FIGURE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET DYNAMICS
FIGURE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2021 VS 2027 (%)
FIGURE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2021 VS 2027 (USD BILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2027
FIGURE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, 2019-2027 (USD BILLION)
FIGURE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, 2019-2027 (USD BILLION)
FIGURE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 17. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, 2019-2027 (USD BILLION)
FIGURE 18. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 19. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 20. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2027
FIGURE 22. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, 2019-2027 (USD BILLION)
FIGURE 23. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 24. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, 2019-2027 (USD BILLION)
FIGURE 25. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 26. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, 2019-2027 (USD BILLION)
FIGURE 27. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 28. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2021 VS 2027 (%)
FIGURE 29. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2021 VS 2027 (USD BILLION)
FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2027
FIGURE 31. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, 2019-2027 (USD BILLION)
FIGURE 32. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 33. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, 2019-2027 (USD BILLION)
FIGURE 34. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 35. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, 2019-2027 (USD BILLION)
FIGURE 36. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 37. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 38. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 39. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 40. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2027
FIGURE 41. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 47. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2027
FIGURE 49. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 51. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 52. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2027
FIGURE 53. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 56. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 58. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 59. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 60. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 61. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 64. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 65. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 66. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 67. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2027
FIGURE 68. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 69. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 70. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 71. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 72. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 73. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 74. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 75. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 76. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 77. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 78. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 79. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 80. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 81. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL RESPIRATORY DISEASE VACCINE MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2019-2027 (USD BILLION)
TABLE 7. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY STATE, 2019-2027 (USD BILLION)
TABLE 9. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY REGION, 2019-2027 (USD BILLION)
TABLE 12. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY STATE, 2019-2027 (USD BILLION)
TABLE 14. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY REGION, 2019-2027 (USD BILLION)
TABLE 17. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY STATE, 2019-2027 (USD BILLION)
TABLE 19. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 20. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2019-2027 (USD BILLION)
TABLE 22. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY STATE, 2019-2027 (USD BILLION)
TABLE 24. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 25. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 26. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 27. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 28. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 30. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 31. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 32. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 33. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 35. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 36. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 37. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY REGION, 2019-2027 (USD BILLION)
TABLE 38. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 39. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY STATE, 2019-2027 (USD BILLION)
TABLE 40. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 41. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 42. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 43. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2019-2027 (USD BILLION)
TABLE 44. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 45. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY STATE, 2019-2027 (USD BILLION)
TABLE 46. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 47. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 48. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2019-2027 (USD BILLION)
TABLE 49. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 50. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY STATE, 2019-2027 (USD BILLION)
TABLE 51. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 53. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2019-2027 (USD BILLION)
TABLE 54. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 55. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY STATE, 2019-2027 (USD BILLION)
TABLE 56. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 58. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 59. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 60. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 61. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 62. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 63. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 64. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 65. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 66. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 67. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 68. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 69. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 70. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 71. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 72. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 73. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 74. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 75. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 76. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 77. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 78. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 79. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 80. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2019-2027 (USD BILLION)
TABLE 81. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 82. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 83. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 84. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 85. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 86. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 87. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 88. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 89. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 90. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 91. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 92. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 93. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 94. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 95. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 96. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 97. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 98. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 99. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 100. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 101. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 102. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 103. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 104. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 105. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 106. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 107. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 108. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 109. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 110. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 111. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 112. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 113. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 114. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 115. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 116. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 117. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 118. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 119. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 120. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 121. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 122. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 123. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 124. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 125. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 126. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 127. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 128. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 129. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 130. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 131. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 132. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 138. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 139. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 140. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 141. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 142. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 143. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 144. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 145. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 146. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 147. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 148. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 149. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 150. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 151. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 152. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 153. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 154. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 155. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 156. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 157. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 158. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 159. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 160. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 161. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 162. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 163. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 164. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 165. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 166. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 167. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 168. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 169. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 170. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 171. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 172. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 173. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 174. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 175. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 176. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 177. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 178. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 179. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2019-2027 (USD BILLION)
TABLE 180. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2019-2027 (USD BILLION)
TABLE 181. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2019-2027 (USD BILLION)
TABLE 182. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 183. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 184. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 185. GLOBAL RESPIRATORY DISEASE VACCINE MARKET RANKING
TABLE 186. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2021
TABLE 187. GLOBAL RESPIRATORY DISEASE VACCINE MARKET MERGER & ACQUISITION
TABLE 188. GLOBAL RESPIRATORY DISEASE VACCINE MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 189. GLOBAL RESPIRATORY DISEASE VACCINE MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 190. GLOBAL RESPIRATORY DISEASE VACCINE MARKET INVESTMENT & FUNDING
TABLE 191. GLOBAL RESPIRATORY DISEASE VACCINE MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 192. GLOBAL RESPIRATORY DISEASE VACCINE MARKET: LICENSE & PRICING

Companies Mentioned

  • AstraZeneca
  • Bavarian Nordic
  • Bayer AG
  • Bio Farma
  • Dynavax Technologies Corporation
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Seqirus USA Inc.
  • Serum institute of India Private Limited

Methodology

Loading
LOADING...